Overview

Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute on Aging (NIA)
Treatments:
Petrolatum
Sirolimus